within Pharmacolibrary.Drugs.ATC.D;

model D07AC18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.02,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Prednicarbate is a non-halogenated topical corticosteroid used for its anti-inflammatory, antipruritic, and vasoconstrictive properties in the treatment of dermatological conditions such as atopic dermatitis and eczema. It is approved for topical use and is available as creams and ointments primarily in Europe.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) data available in the literature for prednicarbate. PK parameters provided below are rough estimates for healthy adult human subjects based on class information for topical corticosteroids with similar lipophilicity and molecular characteristics.</p><h4>References</h4><ol><li><p>Kellner, HM, et al., &amp; Oekonomopulos, R (1986). [Pharmacokinetics and biotransformation following topical use of the local corticoid prednicarbate]. <i>Zeitschrift fur Hautkrankheiten</i> 61 Suppl 1 18–40. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3705671/&quot;>https://pubmed.ncbi.nlm.nih.gov/3705671</a></p></li><li><p>Lange, K, et al., &amp; Schäfer-Korting, M (1997). Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. <i>Pharmaceutical research</i> 14(12) 1744–1749. DOI:<a href=&quot;https://doi.org/10.1023/a:1012183914011&quot;>10.1023/a:1012183914011</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9453063/&quot;>https://pubmed.ncbi.nlm.nih.gov/9453063</a></p></li><li><p>Lombardi Borgia, S, et al., &amp; Schäfer-Korting, M (2008). In vitro skin absorption and drug release - a comparison of six commercial prednicarbate preparations for topical use. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 68(2) 380–389. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2007.05.003&quot;>10.1016/j.ejpb.2007.05.003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17574402/&quot;>https://pubmed.ncbi.nlm.nih.gov/17574402</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AC18;
